Skip to main content
. Author manuscript; available in PMC: 2018 Jun 17.
Published in final edited form as: Bioconjug Chem. 2018 Feb 9;29(2):538–545. doi: 10.1021/acs.bioconjchem.8b00028

Figure 3.

Figure 3

(A) Experimental scheme. (B) Full pretargeted ex vivo biodistribution of BxPC3-tumor bearing mice that were injected 10 min prior to the radioligand with either high (120 nmol Tz) or low (24 nmol Tz) amounts of DP–Tz. (C) Ex vivo tumor-to-blood (TTB) ratios obtained for different amounts of DP–Tz and lag times between DP–Tz and radiotracer injection. (D) Corresponding PET images showing the significantly improved TTB ratios using the newly developed DP–Tz.